Imetelstat Sodium + Placebo
Phase 2/3Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelodysplastic Syndromes
Conditions
Myelodysplastic Syndromes
Trial Timeline
Jan 12, 2016 → Oct 13, 2026
NCT ID
NCT02598661About Imetelstat Sodium + Placebo
Imetelstat Sodium + Placebo is a phase 2/3 stage product being developed by Geron for Myelodysplastic Syndromes. The current trial status is active. This product is registered under clinical trial identifier NCT02598661. Target conditions include Myelodysplastic Syndromes.
What happened to similar drugs?
7 of 19 similar drugs in Myelodysplastic Syndromes were approved
Approved (7) Terminated (7) Active (7)
Hype Score Breakdown
Clinical
15
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02598661 | Phase 2/3 | Active |
Competing Products
20 competing products in Myelodysplastic Syndromes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 23 |
| JSP191 | Jasper Therapeutics | Phase 1 | 11 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 15 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 14 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 35 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 35 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 35 |
| decitabine + decitabine | Eisai | Phase 2 | 35 |
| decitabine + azacitidine | Eisai | Approved | 35 |
| Decitabine | Eisai | Phase 2 | 27 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 29 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 35 |
| Subcutaneous Decitabine | Eisai | Phase 1 | 21 |
| Decitabine | Eisai | Phase 2 | 35 |
| Galunisertib + Placebo | Eli Lilly | Phase 2/3 | 38 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 32 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 24 |
| Decitabine | Johnson & Johnson | Phase 2 | 35 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 27 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 35 |